Search clinical trials for: Anti-PD-L1 monoclonal antibody
Total 103122 results
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Shanghai Zhongshan HospitalRecruiting
-
Huabo Biopharm Co., Ltd.Recruiting
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Imugene LimitedActive, not recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Shanghai Zhongshan HospitalRecruitingHepatocellular CarcinomaChina
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingCervical Cancer | Advanced Solid TumorChina
-
Maastricht Radiation OncologyMaastricht University Medical Center; Zuyderland Medical CentreCompleted
-
Zhongnan HospitalRecruiting
-
Baodong QinUnknown
-
Pyrotech Therapeutics, Inc.RecruitingLocally Advanced or Metastatic Solid TumorsUnited States
-
NSABP Foundation IncHoffmann-La Roche; Genentech, Inc.Active, not recruitingTriple Negative Breast CancerUnited States, Canada
-
Huabo Biopharm Co., Ltd.RecruitingTumor, SubjectsUnited States, China
-
Leiden University Medical CenterRadboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaboratorsActive, not recruitingUterine Neoplasms | Endometrial Neoplasms | Endometrium CancerNetherlands
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Grand Hôpital de CharleroiCliniques universitaires Saint-Luc- Université Catholique de LouvainActive, not recruiting
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
MedImmune LLCCompletedNSCLC | Lung Cancer | Non-small Cell Lung CancerUnited States, France, Italy, Spain, Belgium, United Kingdom, Korea, Republic of, Australia, Taiwan
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.UnknownAdvanced Solid TumorsChina
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
University of Colorado, DenverAstraZenecaWithdrawnPancreatic CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Shanghai Zhongshan HospitalRecruitingHepatocellular CarcinomaChina
-
Monika Joshi, MDAstraZenecaActive, not recruiting
-
Hoffmann-La RocheCompletedBladder CancerUnited States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
-
Oncovir, Inc.Chevy Chase Healthcare, Chevy Chase MD; Mt. Sinai School of Medicine, New York... and other collaboratorsTerminated
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
University of Texas Southwestern Medical CenterAstraZenecaTerminatedFallopian Tube Cancer | Primary Peritoneal Carcinoma | Recurrent Epithelial Cancer of OvaryUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...NanoMab Technology (UK) LimitedCompletedNon-Small Cell Lung CancerChina
-
ARCAGY/ GINECO GROUPAstraZenecaActive, not recruiting
-
Groupe Hospitalier Pitie-SalpetriereVanderbilt University Medical Center; Vanderbilt University; Institute of Cardiometabolism...CompletedMyocarditis | Cardiac ComplicationFrance
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint InhibitorChina